Drug Database · Clinicians

Medium chain triglyceride + Olive oil + Purified fish oil + Soy bean oil

Brands (1) SMOFlipidShow all

Part of: Parenteral nutrition products (Drug Index, by product type)

Parenteral nutrition regimen PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH product PN kidney notes reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Parenteral nutrition: kidney notes

Brand-specific kidney notes for the parenteral nutrition products filed under this generic: composition from the manufacturer SmPC or package insert, its kidney-related text, and how the product fits the guideline. Sources are listed under References.

Kidney notes: SMOFlipid

SMOFlipid 20% (Fresenius Kabi Austria GmbH) is a lipid emulsion of soybean oil, medium-chain triglycerides, olive oil and fish oil, used as the energy and essential fatty acid component of parenteral nutrition. Philippine registrations: 100 ml and 250 ml glass bottles.

Composition

Per presentationper 1000 ml
Soybean oil, refined (g)60
Medium-chain triglycerides (g)60
Olive oil, refined (g)50
Fish oil, rich in omega-3 fatty acids (g)30
Energy (kcal)2000
Sodium, up to (mmol)5
  • Osmolality approximately 380 mosm/kg; pH approximately 8 (SmPC). Contains no potassium; phosphate from egg phospholipids is not stated in the SmPC.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Adults: 1.0 to 2.0 g fat/kg body weight per day (5 to 10 ml/kg/day); infusion rate should not exceed 0.15 g fat/kg/hour (SmPC 4.2).

Kidney notes

  • Contraindicated in "severe renal insufficiency without access to hemofiltration or dialysis" (SmPC 4.3).
  • Give with caution in impaired lipid metabolism, which may occur in renal failure; clinical data in renal failure are limited (SmPC 4.4).
  • Monitor serum triglycerides: they should generally not exceed 3 mmol/l during infusion (SmPC 4.4).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 27: "There is not enough evidence to support the routine use of omega-3 polyunsaturated fatty acids (PUFA) supplements or PN solutions enriched with omega-3 PUFA in hospitalized patients with AKI, AKI on CKD or CKD with KF." Grade of recommendation GPP – Strong consensus (95.8% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)

Bottom line

A mixed-oil lipid emulsion; in severe renal insufficiency it needs dialysis or hemofiltration access. Check triglycerides, which can rise in kidney failure. ESPEN does not support routine omega-3-enriched PN in kidney disease, so the fish oil content is not a reason to prefer it for kidney patients.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Dosage forms

Philippines

  • Emulsion for infusion: 200 mg/mL

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Medium chain triglyceride + Olive oil + Purified fish oil + Soy bean oil as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Medium chain triglyceride + Olive oil + Purified fish oil + Soy bean oil
Package insert
SMOFlipidSoy Bean Oil + Medium Chain Triglyceride + Olive Oil + Purified Fish Oil
200 mg / mL (20%) Emulsion for Infusion (IV)Light weight Type II Glass Bottle with butyl-rubber Stopper and aluminium cap x 100 mL and 250 mL (Box of 10's)
Rx
Fresenius Kabi Austria GmbHAustria
Fresenius Kabi Philippines, Inc.
DR-XY31918
Jun 27, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  2. Fresenius Kabi. (2020). SMOFlipid 200 mg/ml emulsion for infusion, glass bottle (PA2059/062/001) [Summary of product characteristics; text revised May 2020]. Health Products Regulatory Authority. https://assets.hpra.ie/products/Human/18424/Licence_PA2059-062-001_28052020120241.pdf
  3. Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., Jonckheer, J., Singer, P., & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition, 40(4), 1644–1668. https://doi.org/10.1016/j.clnu.2021.01.028

renalcarematters.com content: Parenteral nutrition kidney notes (SMOFlipid): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .